Kirchgraber Paul R
- SEC CIK
- 0001791393
No open-market purchases or sales filed in the past year.
Current role at each company
- LH Labcorp Holdings Inc.CEO, Covance Drug Developmentas of May 23, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Kirchgraber Paul R as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 23, 2023 (view filing) | May 19 | 4 days | Kirchgraber Paul RCEO, Covance Drug Development | SSale | −4.30K | $216.91 | −$932.7K | −24.9%12.9K after | |
| Feb 23, 2023 (view filing) | Feb 21 | 2 days | Kirchgraber Paul RCEO, Covance Drug Development | SSale | −8.00K | $250.58 | −$2.00M | −46.9%9.07K after |